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Abstract
AIM
To assess the relationship between the presence of 
toll-like receptor 4 (TLR4) polymorphisms and bacterial 
infections in cirrhotic patients with ascites. 
METHODS
We prospectively included consecutive patients with 
cirrhosis and ascites hospitalized during a 6-year 
period. Patients with human immunodeficiency virus 
(HIV) infection or any other immunodeficiency, patients 
with advanced hepatocellular carcinoma (beyond Milan’
s criteria) or any other condition determining poor 
short-term prognosis, and patients with a permanent 
urinary catheter were excluded. The presence of D299G 
and/or T399I TLR4 polymorphisms was determined 
by sequencing and related to the incidence and 
probability of bacterial infections, other complications 
of cirrhosis, hepatocellular carcinoma, and mortality 
during follow-up. A multivariate analysis to identify 
predictive variables of mortality in the whole series was 
performed. 
RESULTS
We included 258 patients: 28 (10.8%) were carriers 
of D299G and/or T399I TLR4 polymorphisms 
(polymorphism group) and 230 patients were not (wild-
type group). The probability of developing any bacterial 
infection at one-year follow-up was 78% in the 
polymorphism group and 69% in the wild-type group 
(P  = 0.54). The one-year probability of presenting 
infections caused by gram-negative bacilli (51% vs  
44%, P  = 0.68), infections caused by gram-positive 
cocci (49% vs  40%, P  = 0.53), and spontaneous 
bacterial peritonitis (29% vs  34%, respectively, P  = 
0.99) did not differ between the two groups. The one-
year probability of transplant-free survival was 55% 
in the polymorphism group and 66% in the wild-type 
group (P  = 0.15). Multivariate analysis confirmed that 
age, Child-Pugh score, active alcohol intake, previous 
hepatic encephalopathy, hepatocellular carcinoma and 
serum creatinine were associated with a higher risk of 
death during follow-up. 
CONCLUSION
Genetic polymorphisms D299G and/or T399I of TLR4 
do not seem to play a relevant role in the predisposition 
of cirrhotic patients with ascites to bacterial infections. 
Key words: Cirrhosis; Genetic polymorphisms; Toll-like 
receptor 4; Bacterial infections; Ascites
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: Patients with cirrhosis present a high incidence 
of bacterial infections. Toll-like receptor (TLR) 4 
genetic polymorphisms, particularly D299G, have been 
previously associated with an increased predisposition 
to infection in several populations. In the present 
study, genetic polymorphisms D299G and/or T399I 
of TLR4 do not seem to play a relevant role in the 
predisposition to develop bacterial infections or in the 
prognosis of cirrhotic patients with ascites. Age, serum 
creatinine, Child-Pugh score, active alcohol intake, 
previous hepatic encephalopathy and the presence of 
hepatocellular carcinoma were independent predictive 
factors of mortality during follow-up. 
Alvarado-Tapias E, Guarner-Argente C, Oblitas E, Sánchez E, 
Vidal S, Román E, Concepción M, Poca M, Gely C, Pavel O, 
Nieto JC, Juárez C, Guarner C, Soriano G. Toll-like receptor 4 
polymorphisms and bacterial infections in patients with cirrhosis 
and ascites. World J Hepatol 2018; 10(1): 124-133  Available 
from: URL: http://www.wjgnet.com/1948-5182/full/v10/i1/124.
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INTRODUCTION
Cirrhotic patients, particularly those with decom­
pensated disease, are at high risk to develop bacterial 
infections. Such infections may in turn precipitate other 
decompensations of cirrhosis, including renal failure, 
hepatic encephalopathy, variceal bleeding and acute­
on­chronic liver failure (ACLF). As a consequence, 
bacterial infections have a significant impact on survival 
in these patients[1­3]. 
The most common bacteria causing spontaneous 
bacterial peritonitis (SBP), spontaneous bacteremia 
and urinary tract infections are enteric gram­negative 
bacteria (mainly Escherichia coli), while gram­
positive bacteria are more likely to be the causative 
agent in cases of pneumonia (Streptococcus) and 
instrumentation­related infection (Staphylococcus)[1­3]. 
The relative importance of gram­positive pathogens 
has increased in recent years due to norfloxacin 
prophylaxis and invasive procedures. However, bacterial 
translocation of gram­negative gut bacteria continues to 
be an important step in the pathogenesis of infections 
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in cirrhotic patients, mainly in those with advanced liver 
insufficiency and portal hypertension[1­4] because of a 
failure in their local and systemic immune defenses[5].
Toll­like receptors (TLR) are a family of transmembrane 
receptors found on monocytes, macrophages and 
neutrophils, and play a key role in the innate immune 
response. Their main function is the recognition of 
pathogen­associated molecular patterns (PAMPs), 
such as lipopolysaccharide (LPS), lipoproteins and 
peptidoglycans[6].
TLR4 in particular recognizes LPS from gram­negative 
bacilli. The presence of the genetic polymorphisms 
D299G (rs4986790) and/or T399I (rs4986791) of TLR4 is 
believed to increase susceptibility to developing infections 
in some populations[7­10] including cirrhotic patients[10­14]. 
In a previous retrospective study, an association between 
the presence of the D299G TLR4 polymorphism and a 
predisposition to developing bacterial infections in cirrhosis 
patients was observed[14]. However, this association has 
yet to be evaluated prospectively. 
The aim of this study was to prospectively assess 
the relationship between the presence of D299G and/
or T399I TLR4 polymorphisms and the incidence of 
bacterial infections in cirrhotic patients with ascites.
MATERIALS AND METHODS
Patients
We prospectively included all cirrhotic patients with 
ascites hospitalized in the Department of Gastroenter­
ology at Hospital de la Santa Creu i Sant Pau, a tertiary 
hospital in Barcelona, Spain, from May 2005 to May 
2011. We included the patients to the study the first 
day of admission at the hospital. Biopsy and clinical, 
analytical and ultrasonographic data were used to 
diagnose cirrhosis. With the aim of minimizing the 
effects of confounding factors in the development of 
bacterial infections, the course of cirrhosis and survival, 
patients with human immunodeficiency virus (HIV) 
infection or any other immunodeficiency, patients with 
advanced hepatocellular carcinoma (beyond Milan’s 
criteria) or any other condition determining poor short­
term prognosis, and patients with a permanent urinary 
catheter were excluded. At admission, we recorded 
demographic, clinical and analytical characteristics 
(etiology of cirrhosis, degree of liver insufficiency, renal 
function), and previous infections and decompensations 
of cirrhosis. 
We obtained blood samples for a posterior genetic 
analysis of TLR4 polymorphisms on the first day of 
admission. Patients were assigned to two groups: 
Subjects with D299G and/or T399I TLR4 polymorphisms 
(polymorphism group) and subjects without (wild­type 
group).
The study was approved by the Research Ethics 
Committee at Hospital de la Santa Creu i Sant Pau. All 
patients gave consent to be included in the study after 
receiving appropriate verbal and written information.
Follow-up evaluation
We prospectively determined the incidence and the 
probability to present infections, other complications 
of cirrhosis, hepatocellular carcinoma, and mortality 
during follow­up; and we compared patients from 
the two groups. Follow­up was performed through 
regular outpatients visits with a frequency according 
to patient’s clinical condition but at least twice a year, 
and hospitalizations. A multivariate analysis to identify 
predictive variables of bacterial infection and mortality 
in the whole series was performed. 
Spontaneous bacterial peritonitis (SBP) was 
diagnosed on the basis of an ascitic fluid neutrophil 
polymorphonuclear cell count ≥ 250/mm3 with or 
without positive culture[4]. Bacterascites was defined 
as the presence of a positive culture with a neutrophil 
polymorphonuclear count < 250/mm3 in ascitic fluid[4]. 
Bacteremia was diagnosed when blood cultures were 
positive. Conventional criteria were applied for the 
diagnosis of urinary tract infections, pneumonia, 
cellulitis and other infections[1]. Secondary bacterial 
peritonitis and postoperative wound infections were 
excluded from this analysis, since TLR polymorphisms 
are unlikely to influence the bacteria responsible for 
these infections and including them would possibly 
have biased the analysis of the results. 
Genomic DNA extraction and polymorphism genotyping
Genomic DNA was extracted from buffy­coat fraction by 
using QIAmp DNA blood minikit (Qiagen Inc., Valencia, 
CA, United States). Sequencing was performed by 
Macrogen Inc, South Korea using BigDye (Applied 
Biosystem) chemistry after the PCR­amplified DNA 
fragment was confirmed. The sequencing primer 
used for TLR4 Asp299Gly (D299G, rs4986790) was 
5’­TGGAATGCTGGAAATCCAGA­3’, and for Thr399Ile 
(T399I, rs4986791) was 5’­CTCTAGAGGGCCTGTGCA­3’.
Statistical analysis
Data are expressed as mean ± SD or frequencies. Results 
were analysed using the Fisher exact test for qualitative 
variables. For quantitative parameters the normal 
distribution was confirmed with Kolmogorov-Smirnov or 
Shapiro­Wilk tests. We used the nonparametric Mann­
Whitney test for non­normally distributed data, and 
the Student’s “t” test for normally distributed data. The 
probabilities of bacterial infections and survival were 
calculated using the Kaplan Meier method and compared 
with the log rank test. A multivariate analysis including 
the variables with a P value < 0.05 in the univariate 
analysis was performed using Cox proportional hazards 
regression to identify independent predictive factors of 
bacterial infection and survival. A P value < 0.05 was 
considered statistically significant. Statistical analysis 
was performed using the IBM Corp. Released 2013 
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All patients presented ascites with or without other 
current complications of cirrhosis, such as bacterial 
infection, variceal bleeding, hepatic encephalopathy, 
hepatorenal syndrome, or other admission causes. 
We evaluated patients with and without previous 
decompensations of cirrhosis. Seventy­four of the 
332 patients were excluded for the following reasons: 
9 patients due to HIV infection, one due to variable 
common immunodeficiency, 45 due to advanced 
hepatocellular carcinoma, 12 due to other conditions 
associated with a poor short­term prognosis (two 
lung neoplasia, one ovarian neoplasia, one bladder 
neoplasia, one lymphoma, one brain neoplasia, four 
severe cardiac failure, and two advanced respiratory 
insufficiency), and 7 due to permanent urinary 
catheter. Finally, 258 patients were included in the 
study. The retrospective data of the first 111 patients 
was previously published in a preliminary study from 
our group[14]. 
Analysis of TLR4 polymorphisms showed 28 
patients (10.8%) were carriers of D229G and/or T399I 
polymorphisms. All patients were heterozygous and 
no homozygous patients were detected. Twenty­five 
patients (9.7%) had both polymorphisms, one patient 
was a carrier of the D299G polymorphism only and 
two were carriers of the T399I polymorphism only. 
Patients were then separated into two groups: 28 
patients (10.8%) were D299G and/or T399I TLR4 
polymorphism (polymorphism group) carriers and 230 
who were not (wild­type group).
Table 1 summarizes the clinical and analytical 
characteristics of the both groups at inclusion in the 
study. We found no statistical differences between 
the two groups regarding demographics, etiology 
of cirrhosis, degree of liver insufficiency assessed 
by the Child­Pugh and MELD scores, previous 
decompensations of cirrhosis, current medications, 
type of first decompensation or cause of current 
admission. However, previous hepatic encephalopathy 
was more frequent and serum creatinine had a more 
elevated level in the polymorphism group than in the 
wild­type group.
The mean follow­up in all patients was 26.6 ± 31.7 
mo, 16.9 ± 25.4 mo in the polymorphism group and 
27.8 ± 32.2 mo in the wild­type group (P = 0.04). 
Three patients (10.7%) in polymorphism group and 
16 patients (7%) in wild­type group (P = 0.47) were 
referred to another center to be evaluated for liver 
transplantation, and therefore censored at that time 
for the present study. Within the group of patients 
with alcoholic cirrhosis, 86/140 (61.4%) had active 
alcohol use at inclusion in the study: 9/14 (64.3%) 
in the polymorphism group and 77/126 (61.1%) in 
the wild­type group (P = 1.00). Alcohol abstinence 
during follow­up in these patients with active alcohol 
consumption at inclusion was 48/86 patients (55.8%): 
4/9 (44.4%) in the polymorphism group and 44/77 
IBM SPSS Statistics for Windows, Version 22.0; IBM 
Corp, Armonk, NY, United States.
RESULTS
Patients’ characteristics
From May 2005 until May 2011, 332 cirrhotic patients 
with ascites were admitted to the Department of Gas­
troenterology and assessed for inclusion in the study. 
Table 1  Baseline characteristics of patients from the 






(n  = 28) (n  = 230)
Age (yr) 65.93 ± 12.1 64.90 ± 12.7 0.74





Cause of cirrhosis (%) 0.07
   Alcohol 14 (50) 125 (54.3)
   Hepatitis C virus 11 (39.3) 82 (35.7)
   Hepatitis B virus 0 (0) 8 (3.5)
   Alcohol + HCV/HVB 6 (21.4) 18 (7.8)
   Others 3 (10.7) 22 (9.6)
Active alcoholism (%) 9/20 (45) 80/143 (55.9) 0.84
Diabetes mellitus (%) 9 (32.1) 75 (32.6) 1.00
Child-Pugh score 8.25 ± 1 8.31 ± 1.6 0.95
MELD score 15.29 ± 4.8 15.35 ± 6.2 0.69
Previous decompensations (%) 20 (71.4) 160 (69.6) 1.00
Previous ascites (%)  19 (67.9) 151 (65.7) 1.00
Previous encephalopathy (%)  13 (46.4) 51 (22.2)   0.009
Previous variceal bleeding (%) 7 (25) 54 (23.5) 0.82
Previous spontaneous bacterial 
peritonitis (%)
   3 (10.7) 16 (7) 0.44
Hepatocellular carcinoma (%)   4 (14.3) 26 (11.3) 0.55
Norfloxacin prophylaxis (%)   4 (14.3) 18 (7.8) 0.28
Beta-blockers (%) 10 (35.7) 74 (32.2) 0.68
Diuretics (%) 15 (53.6) 135 (58.7) 0.69
Serum sodium (mmol/L) 135.14 ± 6.3 135.14 ± 9.8 0.78
Serum urea (mmol/L)   9.6 ± 4.1 9.6 ± 9.1 0.18
Serum creatinine (µmol/L) 117.29 ± 59.6 100.6 ± 59.9 0.01
Serum bilirubin (µmol/L)   54.7 ± 59.7 43 ± 34.1 0.64
Serum albumin (g/L) 26.6 ± 5.5 27.9 ± 5.5 0.43
Prothrombin time ratio   1.51 ± 0.24 1.57 ± 0.67 0.65
Ascitic fluid total protein (g/L) 13.9 ± 6.6 15.6 ± 10.7 0.30
First decompensation1
   Ascites (%) 19 (67.8) 165 (71.7) 0.66
   Encephalopathy (%)   3 (10.7)   6 (2.6) 0.06
   Variceal bleeding (%)   4 (14.3)   44 (19.1) 0.79
   Infection (%) 2 (7.1) 12 (5.2) 0.65
Cause of current admission2
   Ascites (%) 8 (28.6) 101 (43.9) 0.15
   Encephalopathy (%) 5 (17.9) 22 (9.6) 0.18
   Variceal bleeding (%) 3 (10.7)   31 (13.5) 1.00
   Spontaneous bacterial 
   peritonitis (%)
6 (21.4)   33 (14.3) 0.39
   Other infection (%) 3 (10.7)  13 (5.7) 0.39
   Other (%) 3 (10.7) 30 (13) 1.00
1Refers to the first decompensation that patients presented in the past 
(in patients with previous decompensation) or at present admission 
(in patients without previous decompensation); 2Main cause of the 
hospitalization in which the patient was included to the study. Data are 
presented as mean ± SD or frequencies (%). MELD: Model for end-stage 
liver disease; HCV: Hepatitis C virus; HBV: Hepatitis B virus.
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(57.1%) in the wild­type group (P = 0.50).  
Infections during follow-up 
Table 2 shows bacterial infections diagnosed in the two 
groups during follow­up. Considering all the infections, 
no statistical differences were observed between the 
two groups in terms of the incidence and number of 
infections per patient during the follow­up period, 
although there was a slight trend to a higher number 
of infections per patient in the polymorphism group 
than in the wild­type group. The incidence and the 
number of infections per patient caused by gram­
negative bacilli or gram­positive cocci was similar in 
both groups although there was a higher, though non­
statistically significant, incidence of gram-positive cocci 
infections in the polymorphism group compared to the 
wild­type group (50% vs 37.8% P = 0.22). 
Table 3 shows the different types of bacterial 
infections caused by gram­negative bacilli or 
gram­positive cocci. There were not any statistical 
differences between both groups regarding the type of 
infection or the causative bacteria in the different types 
of infection. A trend for higher incidence of pneumonia 
was observed in the polymorphism group (17.9% 
vs 8.7%, P = 0.08), but this was not statistically 
significant.
The probability of developing a bacterial infection at 
one­year of follow­up was 78% in the polymorphism 
group and 69% in the wild­type group (P = 0.54) 
(Figure 1A). The likelihood of infections caused by 
gram­negative bacilli after one year was 51% for 
the polymorphism group and 44% for the wild­type 
group (P = 0.68) (Figure 1B), for infections caused 
by gram­positive cocci it was 49% vs 40% (P = 0.53) 
(Figure 1C), and for spontaneous bacterial peritonitis 
it was 29% vs 34%, respectively (P = 0.99) (Figure 
1D). Multivariate analysis by Cox regression showed 
that age (HR 1.023, 95%CI: 1.010­1.035, P ≤ 
0.001), MELD score (HR 1.034, 95%CI: 1.010­1.059, 
P = 0.006), and previous hepatic encephalopathy 
(HR 1.570, 95%CI: 1.136­2.169, P = 0.006) were 
associated with a higher risk of infection during follow­
up. The presence of TLR4 polymorphisms was not 
associated with the risk of infection in the univariate 
analysis or in the multivariate analysis. 
Other complications of cirrhosis and survival
The likelihood of suffering hepatic encephalopathy 
after one year was 43% for the polymorphism group, 
and 41% for the wild­type group (P = 0.97), while the 
probability of developing variceal hemorrhage after 
one year was 17% and 12%, respectively (P = 0.35). 
The likelihood of developing a new hepatocellular 
carcinoma at two­years of follow­up was 7.1% for the 
polymorphism group and 6.3% for the wild­type group 
(P = 0.87).
The mortality during follow­up was 46.4% (13/28) 
in the polymorphism group and 46.5% (107/230) 
in the wild­type group (P = 1.00). The causes of 
mortality were ACLF or liver insufficiency in 46.15% 
(6/13) in the polymorphism group and 51.4% (55/107) 
in the wild­type group (P = 0.77); infection in 15.4% 
(2/13) and 20.6 % (22/107) (P = 1.00), variceal 
bleeding in 7.7% (1/13) and 8.4% (9/107) (P = 1.00), 
and hepatocellular carcinoma in 7.7% (1/13) and 5.6 
% (6/107) (P = 0.56). In the polymorphism group, 
another three patients (23%) died from other causes 
unrelated to the liver disease: two from coronary heart 
Table 2  Overall incidence, number of episodes and causative 
bacteria of infections in patients from the polymorphism 






(n  = 28) (n  = 230)
Total infections
   Patients (%) 22 (78.6) 171 (74.3) 0.81
   Number of infections 63 437
   Number per patient 2.25 ± 2.40 1.92 ± 2.19 0.46
Infections caused by gram-negative bacilli
   Patients (%) 11 (39.2) 102 (44.3) 0.84
   Number per patient 0.86 ± 1.84 0.77 ± 1.25 0.75
Infections caused by gram-positive cocci
   Patients (%) 14 (50) 87 (37.8) 0.22
   Number per patient 0.64 ± 0.73 0.60 ± 1.009 0.83
Data are presented as mean ± SD or frequencies (%).
Table 3  Type of infections in patients from the polymorphism 






(n  = 28) (n = 230)
Spontaneous bacterial peritonitis
   Patients (%) 10 (35.7) 81 (35.2) 1.00
   Number of spontaneous bacterial 
   peritonitis episodes
15 109
   Number per patient 0.54 ± 0.92 0.47 ± 0.79 0.70
   Caused by gram-negative bacilli (%) 0 (0) 20 (8.7) 0.14
   Caused by gram-positive cocci (%)   3 (10.7)   24 (10.4) 1.00
   Culture negative (%) 12 (42.8)   57 (24.8) 0.06
Bacteremia
   Patients (%) 4 (14.3)   47 (20.4) 0.61
   Number of bacteremia episodes 4 57
   Number per patient 0.14 ± 0.36 0.25 ± 0.55 0.41
   Caused by gram-negative bacilli (%) 1 (3.6) 26 (11.3) 0.79
   Caused by gram-positive cocci (%)   3 (10.7) 31 (13.5) 0.87
Urinary infections
   Patients (%) 13 (46.4) 111 (48.3) 1.00
   Number of urinary infection 
   episodes
30 209
   Number per patient 1.07 ± 2.08 0.91 ± 1.42 0.90
   Caused by gram-negative bacilli (%)   10 (35.7)   80 (34.8) 0.92
   Caused by gram-positive cocci (%) 7 (25)   49 (21.3) 0.74
Other infections
   Patients (%)   9 (32.1)   59 (25.9) 0.50
   Pneumonia (%)   5 (17.9) 20 (8.7) 0.16
   Bacteriascites (%) 2 (7.1) 15 (6.5) 1.00
   Cellulitis (%) 2 (7.1) 13 (5.7) 0.67
Data are presented as mean ± SD or frequencies (%).
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                            0          2          4          6           8         10        12
                                                            t/mo
Wild-type            230       186       164       147      127       113        109
Polymorphism        28        20         16        13          9           7            6
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disease and one from advanced oropharyngeal cancer. 
In the wild­type group, another fourteen patients 
(14%) (P = 0.41 with respect to polymorphism 
group) died from other causes unrelated to the liver 
disease: five from coronary heart disease and nine 
from advanced neoplasia (two lung neoplasm, one 
oropharyngeal cancer, one colon neoplasm, two non­
identified advanced neoplasias, one breast cancer, one 
lymphoma, and one brain cancer). The likelihood of 
transplant­free survival at one year was 55% for the 
polymorphism group and 66% for the wild­type group 
(P = 0.15) (Figure 2), while the figures at two-years of 
follow up were 48% and 57%, respectively (P = 0.16). 
We performed a multivariate analysis to analyse 
the contribution of baseline characteristics and the 
presence of TLR4 polymorphisms on the risk of death. 
In the univariate analysis we found age, HCV (hepatitis 
C virus) infection, active alcohol intake, Child­
Pugh score, MELD score, previous decompensation, 
previous ascites, previous hepatic encephalopathy, 
hepatic encephalopathy at admission, hepatocellular 
carcinoma, treatment with beta­blockers or diuretics, 
serum creatinine, and serum urea were associated 
with a higher risk of death during follow­up (Table 4). 
Multivariate analysis by Cox regression confirmed that 
age, Child­Pugh score, active alcohol intake, previous 
hepatic encephalopathy, hepatocellular carcinoma 
and serum creatinine were associated with a higher 
risk of death during follow­up. The presence of TLR4 
polymorphisms was not associated with mortality in 
Figure 1  One year-probability of infections in the polymorphism group and in the wild-type group. A: All infections; B: Infections caused by gram-negative 
bacilli; C: Infections caused by gram-positive cocci; D: Spontaneous bacterial peritonitis.
Figure 2  One year-probability of transplant-free survival in the polymorphism 
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the univariate analysis or in the multivariate analysis. 
DISCUSSION 
The main finding in the present prospective study was that 
we failed to show significant differences in the incidence 
and number of infections, complications of cirrhosis and 
prognosis between cirrhotic patients with ascites who had 
D299G and/or T399I TLR4 polymorphisms and patients 
who were not carriers of these polymorphisms. 
Infections in patients with cirrhosis are common and 
a major cause of morbidity and mortality[4]. Attempts 
to prevent bacterial infections are therefore reasonable, 
and successful strategies have been developed in recent 
years, particularly those using antibiotic prophylaxis[3,4]. 
Antibiotic prophylaxis, however, mainly in long­term 
treatments, is not devoid of side effects, especially 
the development of bacterial resistances[1,3]. This is a 
serious world-wide problem that decreases the efficacy 
of prophylactic antibiotics and increases morbidity 
and mortality, not only in the general population but 
also in patients with cirrhosis[3]. To minimize bacterial 
resistance it is important to identify the risk factors 
for infection in order to develop comprehensive 
prevention strategies that restrict antibiotic prophylaxis 
to high­risk groups[3]. Many clinical factors have 
been associated with an increased risk of infection in 
cirrhosis, such as high degree of hepatic insufficiency, 
variceal bleeding, low levels of protein in ascites, 
prior spontaneous bacterial peritonitis, and hospital 
admission in the last 3 mo[15]. 
In addition to clinical factors, the relationship 
between genetic variants that can modify the immune 
response and the incidence of infections in cirrhotic 
patients has gained increasing interest in recent 
years[11,14,16­18]. Recent studies in patients with cirrhosis 
have shown that some genetic variants of NOD2 
(nucleotide­binding oligomerization domain­containing 
2), TLR2 and NDP52 (nuclear dot protein 52 kDa) 
are involved in the predisposition to spontaneous 
bacterial peritonitis, probably through alterations at 
the intestinal barrier and the immune response[16­18]. 
The presence of the genetic polymorphisms D299G 
and/or T399I of TLR4 is also thought to modify the 
immune response to LPS from gram­negative bacilli, and 
therefore increase susceptibility to infection in patients 
with cirrhosis[11­14]. In a preliminary retrospective study, 
it was found that cirrhotic patients with D299G TLR4 
polymorphism had more previous infections than wild­
type patients[14]. Therefore, the present study was 
designed to prospectively evaluate whether patients 
diagnosed with cirrhosis and ascites and D299G and/or 
T399I TLR4 polymorphisms had a higher risk of bacterial 
infections during follow­up than wild­type patients. 
However, we observed a non-significant trend to a higher 
predisposition to bacterial infections, infections caused 
either by gram­negative bacilli or by gram­positive 
cocci in the polymorphism group. Regarding the types 
of infection, there was a trend to a higher incidence of 
pneumonia in the polymorphism group, but the incidence 
of other infections more characteristic of cirrhosis such 
as SBP, urinary infection or bacteremia was similar in 
the two groups. The findings of the present study are 
contradictory with those from our previous preliminary 
retrospective study. However, we consider the results of 
this study more reliable because it was prospective and 
included a higher number of patients.  
These negative results may be due to the low 
prevalence of the polymorphisms evaluated, 10.8% of 
all patients ­ a prevalence similar to that in the general 
population[9,10],  an insufficient number of patients 
studied, and a short follow­up, particularly in the 
polymorphism group. It should be noted, however, that 
we prospectively evaluated a relatively high number of 
patients with decompensated cirrhosis over a 6­year 
period and with a mean overall follow­up of 26.6 ± 
31.7 mo. Moreover, we corrected for the difference 
in the length of follow­up between the two groups by 
calculating Kaplan­Meier curves. We consider that, if we 
failed to show statistically significant differences in the 
Table 4  Univariate and multivariate analysis of baseline 
characteristics regarding the risk of death during follow-up in 
all patients
Variables Univariate Multivariate
HR (95%CI) P  value HR (95%CI) P  value
Age (yr) 1.042 
(1.026-1.056)
< 0.001 1.035 
(1.016-1.054)
< 0.001
HCV etiology 1.99 
(1.385-2.865)
< 0.001
Diabetes mellitus 1.583 
(1.097-2.283)
   0.010
Active alcohol intake 0.353 
(0.230-0.542)
< 0.001 0.568 
(0.345-0.935)
   0.020
Child-Pugh score 1.170 
(1.041-1.317)
   0.008 1.263 
(1.113-1.432)
< 0.001
MELD score 1.036 
(1.007-1.066)




















< 0.001 2.381 
(1.411-4.018)
< 0.001
Previous β-blockers 1.727 
(1.194-2.498)
   0.004
Previous diuretics 1.957 
(1.334-2.869)





< 0.001 1.005 
(1.002-1.007)
< 0.001







   0.032
TLR4 polymorphisms 1.372 
(0.770-2.445)
   0.280
HCV: Hepatitis C virus; MELD: Model for end-stage liver disease. 
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development of infections under these conditions, the 
effect, if any, of the studied polymorphisms has little 
clinical relevance, and their determination should not be 
included in the design of new preventive strategies. 
Our results are in agreement with those of Lee et 
al[19] in patients who underwent a liver transplant. They 
observed no association connecting D299G and T399I 
TLR4 polymorphisms with a risk of developing infection 
or liver disease. Recently, Piñero et al[10] also failed to 
find a relationship between D299G TLR4 polymorphism 
and the development of infections in patients with 
cirrhosis and ascites. These findings are probably due to 
poor functional impact of these polymorphisms and/or 
the multifactorial and complex nature of the immune 
response[11]. 
Patients with polymorphisms of TLR4, the receptor 
to LPS of gram­negative bacilli, would be expected to 
present a greater predisposition to infection caused 
by these bacteria. It is therefore surprising that such 
patients also had a greater, although not statistically 
significant, predisposition to infections caused by gram-
positive cocci and pneumonia, an infection usually 
caused by gram­positive cocci, than wild­type patients. 
Possible explanations could again be the complexity 
of the immune response, and the association between 
polymorphisms of TLR4 and other polymorphisms of 
other PRRs (pattern recognition receptors), such as 
TLR2 (involved in ligand recognition of gram­positive 
cocci) or NOD2, which were not evaluated in this 
study[11].
Inflammation is one of the factors that is increas­
ingly recognized to favor the occurrence of hepatic 
encephalopathy[20,21]. In a previous study, we reported a 
greater occurrence of previous hepatic encephalopathy 
in cirrhotic patients carrying the D299G TLR4 polymorph­
ism than in wild­type group patients[14]. As described 
by Nieto et al[12], cirrhotic patients with D299G and/or 
T399I TLR4 polymorphisms have less spontaneous 
production of IL­6 and IL­10 by peripheral monocytes, 
but a similar production after receptor stimulation 
compared to wild­type patients. This distinct cytokine 
production pattern may favor the development of hepatic 
encephalopathy in cirrhotic patients who are carriers of 
any of these polymorphisms[12]. In the present study, 
although previous episodes of hepatic encephalopathy 
were more frequent in patients with TLR4 polymorphisms 
than in patients in the wild­type group in agreement with 
previous data[12,14], this predisposition was not confirmed 
in the prospective follow­up. 
A different inflammatory response could influence 
the evolution of cirrhosis and survival in patients with 
TLR4 polymorphisms[22]. In the present study a non­
significant trend to higher mortality was observed 
during the follow­up period in patients with TLR4 poly­
morphisms than in patients from the wild­type group. 
Nevertheless, the presence of TLR4 polymorphisms 
neither in the univariate nor in the multivariate analysis 
was a predictive factor of mortality. Moreover, we 
did not observe differences in the cause of mortality 
between patients with TLR4 polymorphisms and wild­
type patients. Most of the independent predictive factors 
of mortality in the multivariate analysis, such as age, 
Child­Pugh score, previous hepatic encephalopathy, 
hepatocellular carcinoma and serum creatinine, coincided 
with previous studies[23]. Regarding active alcoholism, 
this was an independent factor of survival probably 
due to the fact that more than half of patients actively 
drinking at inclusion in the study remained abstinent 
during follow­up. This percentage of abstainers was 
similar to that in previous studies showing that alcohol 
abstinence improves survival in patients with alcoholic 
cirrhosis[24]. In contrast, at the time the present study 
was performed, patients with decompensated cirrhosis 
due to HCV infection were not usually treated with 
antivirals.
Hepatocellular carcinoma is associated with inflamma-
tion. TLR4 stimulation can induce hepatocarcinogenesis[25] 
and increase invasiveness of hepatocellular carcinoma[26]. 
Therefore, a different inflammatory response as a 
consequence of the presence of TLR4 polymorphisms 
could influence the development of hepatocellular 
carcinoma in cirrhotic patients. In the present study, 
a similar likelihood of developing a new hepatocellular 
carcinoma was observed in both patients with TLR4 
polymorphisms and in wild­type patients, though the 
follow­up period was too short to accurately evaluate this 
outcome. 
We conclude that the presence of D299G and/or 
T399I TLR4 polymorphisms in cirrhotic patients with 
ascites is not a relevant risk factor for the development 
of bacterial infections and does not seem to significantly 
modify the evolution of the disease. It would be 
interesting to study the potential role of other genetic 
polymorphisms in the susceptibility to infections and 
the evolution of patients with cirrhosis. 
ARTICLE HIGHLIGHTS
Research background 
Toll-like receptor (TLR) 4 genetic polymorphisms, particularly D299G, have 
been previously associated with an increased predisposition to infection 
in several populations. However, few data regarding the role of these 
polymorphisms in patients with cirrhosis are available. 
Research motivation 
Few data regarding the role of TLR4 genetic polymorphisms in patients with 
cirrhosis are available
Research objectives 
The aim of this study was to prospectively assess the relationship between the 
presence of D299G and/or T399I TLR4 polymorphisms and the incidence of 
bacterial infections in cirrhotic patients with ascites.
Research methods
The present study was designed to confirm the previous retrospective 
data and to further explore the relationship between the presence of TLR4 
polymorphisms and bacterial infections in cirrhotic patients with ascites. The 
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authors included consecutive patients with cirrhosis and ascites hospitalized 
during a 6-year period. The presence of D299G and/or T399I TLR4 
polymorphisms was determined by sequencing and related to the incidence of 
infections during follow-up.
Research results 
The authors included 258 patients: 28 (10.8%) were carriers of D299G and/or 
T399I TLR4 polymorphisms (polymorphism group) and 230 patients were not 
(wild-type group). The probability of developing any bacterial infection at one-
year follow-up was 78% in the polymorphism group and 69% in the wild-type 
group (P = 0.54). The one-year probability of presenting infections caused 
by gram-negative bacilli (51% vs 44%, P = 0.68), infections caused by gram-
positive cocci (49% vs 40%, P = 0.53), and spontaneous bacterial peritonitis 
(29% vs 34%, respectively, P = 0.99) did not differ between the two groups. The 
one-year probability of transplant-free survival was 55% in the polymorphism 
group and 66% in the wild-type group (P = 0.15). 
Research conclusions 
The presence of the genetic polymorphisms D299G and/or T399I of TLR4 does 
not seem to play a relevant role in the predisposition of cirrhotic patients with 
ascites to develop bacterial infections. 
Research perspectives 
To study the potential role of other genetic polymorphisms in the susceptibility 
to infections and the evolution of patients with cirrhosis. 
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